Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Flexible dosing for kidney cancer treatment holds up in real-world data. A retrospective study of 535 metastatic renal cell carcinoma (mRCC) patients found no significant differences in progression-free survival or time to treatment failure between those receiving pembrolizumab every 3 weeks versus every 6 weeks alongside VEGF inhibitors. Researchers caution that longer follow-up is needed before drawing firm conclusions.
Flexible dosing for kidney cancer treatment holds up in real-world data
A new retrospective study presented at IKCS: North America 2026 found that dosing pembrolizumab every 6 weeks (Q6W) produces similar short-term outcomes to the standard every-3-week (Q3W) schedule in patients with metastatic renal cell carcinoma (mRCC). Analyzing data from 535 patients in the Canadian Kidney Cancer Information System, researchers found no meaningful differences in progression-free survival (PFS) or time to treatment failure (TTF) between the two groups after adjusting for risk factors.
Interestingly, the Q6W group showed a statistically significant improvement in overall survival — but researchers urged caution, citing the small Q6W cohort (only 40 patients), differences in partner drugs used, and shorter follow-up time in that group.
Key Takeaways:
Why it matters: Less frequent dosing could reduce treatment burden for patients and healthcare systems alike — but clinicians need more robust data before confidently switching from the established Q3W regimen.